Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477504 | 1.00 | ABL1 (0.39) | ABL1EGFRSRCABL2ESR2 | |
| SCHEMBL25322060 | 0.87 | CCR2 (0.37) | GPR119USP30RORC | |
| SCHEMBL30551004 | 0.87 | CCR2 (0.37) | GPR119USP30RORC | |
| SCHEMBL25322058 | 0.87 | CCR2 (0.37) | GPR119USP30RORC | |
| SCHEMBL31578434 | 0.86 | ABL1 (0.41) | ABL1EGFRSRCABL2USP30 | |
| SCHEMBL30551092 | 0.86 | ABL1 (0.41) | ABL1EGFRSRCABL2USP30 | |
| SCHEMBL24364304 | 0.85 | ESR2 (0.36) | SRCESR2GPR119USP30KDM1A | |
| SCHEMBL25320718 | 0.85 | CCR2 (0.40) | NR1H2NR1H3RORC | |
| SCHEMBL24365657 | 0.85 | SCN9A (0.36) | GPR119USP30NR1H2NR1H3 | |
| SCHEMBL25320724 | 0.85 | CCR2 (0.40) | NR1H2NR1H3RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ABL1 875/4885EGFR 1299/4885SRC 3397/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ABL1 875/4885EGFR 1299/4885SRC 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.